Gerald T. Proehl
Gerald T. Proehl's purchase track record
Gerald T. Proehl has only 1 open-market purchase with a full 6 months of price history after it -- too few to call a track record yet.
| Purchase | Stock | Amount | 3 months | 6 months | S&P 500, 6 mo. |
|---|---|---|---|---|---|
| 11/23/2021 | DRMA | $48K | -49.4% | -67.9% | -16.0% |
Computed by MarketWall from SEC Form 4 filings and daily closing prices (close on the purchase date to the close about 3 and 6 months later). Companies that have since delisted are not included. Past results, not investment advice.
Associated companies
Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 9, 2026
Tenax Pauses TNX-103 Trial Enrollment, Seeks FDA Meeting. Tenax Therapeutics has temporarily paused enrollment in its LEVEL-2 trial for TNX-103 to amend study criteria. The company has also requested a meeting with the FDA to discuss these changes. This development is significant as it involves a key clinical trial, and the stock is currently trading near its 52-week low.
Transaction History
| DRMA | ▲ Buy | Grant | 170,068 | — | 8/16/2026 | View on chart |
| DRMA | ▲ Buy | Grant | 490,196 | — | 12/23/2025 | View on chart |
| DRMA | ▲ Buy | Grant | 122,549 | — | 12/23/2025 | View on chart |
| DRMA | ▲ Buy | Grant | 787,402 | — | 1/21/2025 | View on chart |
| TENX | ▲ Buy | Open Market | 1,666 | — | 8/8/2024 | View on chart |
| DRMA | ▲ Buy | Open Market | 20,000 | $48K | 11/23/2021 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 15, 2026
Dermata Reports Positive Results from Tome Cosmetic Study
Dermata Therapeutics said its Tome Foundational Treatment showed positive topline results in a cosmetic study. The study reported that more than 71% of patients had overall skin improvements at day 29. The company’s shares were active with a volume spike during the session. The stock sits near its 52‑week low and an RSI of 34.5.
Dermata Reports Positive Results from Tome Cosmetic Study. Dermata Therapeutics said its Tome Foundational Treatment showed positive topline results in a cosmetic study. The study reported that more than 71% of patients had overall skin improvements at day 29. The company’s shares were active with a volume spike during the session. The stock sits near its 52‑week low and an RSI of 34.5.